Stakeholder analysis in pharmacogenomics and genomic medicine in Greece

Public Health Genomics. 2014;17(5-6):280-6. doi: 10.1159/000365896. Epub 2014 Sep 9.


Background: The pace of discoveries and advances in genomic research is not reflected in the pace of their translation and incorporation into day-to-day clinical medicine to individualize healthcare decision-making processes. One of the main obstacles is the poor understanding of the policies and the key stakeholders involved in these translation processes.

Methods: We used the computerized version of the PolicyMaker political mapping tool to collect and organize important information about the pharmacogenomics and genomic medicine policy environment, serving as a database for assessments of the policy's content, the major players, their power and policy positions, their interests, and networks and coalitions that interconnect them.

Results and conclusions: Our findings indicate that the genomic medicine policy environment in Greece seems to be rather positive, as the vast majority of the stakeholders express their medium to high support in the initially set goals of genomic medicine policy environment. The Ministry of Health and public healthcare insurance funds seem to oppose it, most likely due to financial constrains. These findings would contribute in selecting and implementing policy measures that will expedite the adoption of genomics into conventional medical interventions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Attitude to Health*
  • Biomedical Research
  • Databases, Factual
  • Genomics
  • Greece
  • Humans
  • Medicine
  • Pharmacogenetics / legislation & jurisprudence*
  • Precision Medicine / methods
  • Public Policy / legislation & jurisprudence*